FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367303744> ?p ?o ?g. }

• W4367303744 abstract "<h3>Objective:</h3> To characterize the Essential Tremor (ET) patient population, explore how US physicians perceive goals and efficacy of ET pharmacotherapy, and determine medications prescribed by neurologists versus primary care physicians (PCPs). <h3>Background:</h3> ET is among the most prevalent movement disorders in adults. However, ET treatment goals and medication prescribing patterns in the US are not well characterized. <h3>Design/Methods:</h3> Forty PCPs and 61 neurologists, including 24 movement disorder specialists (MDS), completed a questionnaire with 7-point Likert items (1=not important/low association, 7=extremely important/strong association) exploring treatment goals and perceived efficacy of medications used in patients with ET under their management. <h3>Results:</h3> Surveyed physicians reported seeing ≈3,000 patients with ET each month in total. 51% were ≥65 years of age; only 3% were ≤18 years of age. Overall, 57% of patients were reported to have moderate/severe ET (neurologists: 61% vs. PCPs: 53%; <i>P</i>=0.17). The most prescribed medications were propranolol (34%), primidone (27%), topiramate (11%), gabapentin (11%), clonazepam (10%), and atenolol (10%). Compared to neurologists, PCPs prescribed primidone to a lower proportion of patients and atenolol to a higher proportion (<i>P</i><0.05). Across physicians, treatment goals rated as most important were maintaining quality of life, maintaining function, reducing hand tremor, tolerability, long-term efficacy, patient compliance, and slowing disease progression (mean importance ≥6.0). The importance of long-term efficacy and patient compliance were rated higher by neurologists than PCPs (<i>P</i><0.01). Both neurologists and PCPs rated medications as having limited-to-moderate effect (mean range: 1.8–4.9) on top-rated attributes, with variation by physician type and medication. <h3>Conclusions:</h3> Most surveyed physicians prioritized patient function and well-being in the treatment of adults with ET. Although PCPs and neurologists differ partly in treatment patterns, goals, and perception of drug efficacies, the overall consensus is that current medications are inadequate in addressing patient-relevant outcomes, highlighting an unmet need for more effective pharmacotherapy. <b>Disclosure:</b> Ms. Gerbasi has received personal compensation for serving as an employee of Sage Therapeutics, Inc.. Ms. Gerbasi has stock in Sage Therapeutics. Ms. Gerbasi has received intellectual property interests from a discovery or technology relating to health care. Dr. Elble has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Jazz. Dr. Elble has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sage . Dr. Elble has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ES Therapeutics. Dr. Elble has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Applied Therapeutics. Dr. Elble has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Praxis. Eddie Jones, BA has nothing to disclose. Mr. Gillespie has nothing to disclose. Mr. Jarvis has nothing to disclose. Mrs. Chertavian has nothing to disclose. Dr. Smith has nothing to disclose. Dr. Bankole has received personal compensation for serving as an employee of Sage Therapeutics. Dr. Bankole has stock in Sage Therapeutics. Dr. Shankar has received personal compensation for serving as an employee of Biogen. Dr. Shankar has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Trinity Lifesciences, Triangle Insights Group. Dr. Shankar has stock in Biogen. Dr. Shankar has stock in Multiple Biotech Companies. Dr. Shih has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Encora Therapeutics. Dr. Shih has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurocrine. Dr. Shih has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Praxis Precision Medicines. Dr. Shih has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Supernus. Dr. Shih has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for WCG Medavante. Dr. Shih has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medtronic. Dr. Shih has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Wiley . The institution of Dr. Shih has received research support from Abbott. The institution of Dr. Shih has received research support from Praxis Precision Medicines. Dr. Shih has received personal compensation in the range of $500-$4,999 for serving as a Consultant with German Accelerator." @default.
• W4367303744 created "2023-04-29" @default.
• W4367303744 creator A5000336590 @default.
• W4367303744 creator A5004708688 @default.
• W4367303744 creator A5005703643 @default.
• W4367303744 creator A5009113890 @default.
• W4367303744 creator A5015739539 @default.
• W4367303744 creator A5048731546 @default.
• W4367303744 creator A5055897665 @default.
• W4367303744 creator A5082371782 @default.
• W4367303744 creator A5084185197 @default.
• W4367303744 creator A5087374969 @default.
• W4367303744 date "2023-04-25" @default.
• W4367303744 modified "2023-09-28" @default.
• W4367303744 title "Treatment Perceptions and Decision-Making Among Physicians Treating Essential Tremor (P5-11.008)" @default.
• W4367303744 doi "https://doi.org/10.1212/wnl.0000000000202157" @default.
• W4367303744 hasPublicationYear "2023" @default.
• W4367303744 type Work @default.
• W4367303744 citedByCount "0" @default.
• W4367303744 crossrefType "proceedings-article" @default.
• W4367303744 hasAuthorship W4367303744A5000336590 @default.
• W4367303744 hasAuthorship W4367303744A5004708688 @default.
• W4367303744 hasAuthorship W4367303744A5005703643 @default.
• W4367303744 hasAuthorship W4367303744A5009113890 @default.
• W4367303744 hasAuthorship W4367303744A5015739539 @default.
• W4367303744 hasAuthorship W4367303744A5048731546 @default.
• W4367303744 hasAuthorship W4367303744A5055897665 @default.
• W4367303744 hasAuthorship W4367303744A5082371782 @default.
• W4367303744 hasAuthorship W4367303744A5084185197 @default.
• W4367303744 hasAuthorship W4367303744A5087374969 @default.
• W4367303744 hasConcept C126322002 @default.
• W4367303744 hasConcept C142724271 @default.
• W4367303744 hasConcept C159110408 @default.
• W4367303744 hasConcept C1862650 @default.
• W4367303744 hasConcept C197934379 @default.
• W4367303744 hasConcept C204787440 @default.
• W4367303744 hasConcept C2776525901 @default.
• W4367303744 hasConcept C2776608144 @default.
• W4367303744 hasConcept C2778375690 @default.
• W4367303744 hasConcept C2779951463 @default.
• W4367303744 hasConcept C2908647359 @default.
• W4367303744 hasConcept C71924100 @default.
• W4367303744 hasConcept C84393581 @default.
• W4367303744 hasConcept C99454951 @default.
• W4367303744 hasConceptScore W4367303744C126322002 @default.
• W4367303744 hasConceptScore W4367303744C142724271 @default.
• W4367303744 hasConceptScore W4367303744C159110408 @default.
• W4367303744 hasConceptScore W4367303744C1862650 @default.
• W4367303744 hasConceptScore W4367303744C197934379 @default.
• W4367303744 hasConceptScore W4367303744C204787440 @default.
• W4367303744 hasConceptScore W4367303744C2776525901 @default.
• W4367303744 hasConceptScore W4367303744C2776608144 @default.
• W4367303744 hasConceptScore W4367303744C2778375690 @default.
• W4367303744 hasConceptScore W4367303744C2779951463 @default.
• W4367303744 hasConceptScore W4367303744C2908647359 @default.
• W4367303744 hasConceptScore W4367303744C71924100 @default.
• W4367303744 hasConceptScore W4367303744C84393581 @default.
• W4367303744 hasConceptScore W4367303744C99454951 @default.
• W4367303744 hasLocation W43673037441 @default.
• W4367303744 hasOpenAccess W4367303744 @default.
• W4367303744 hasPrimaryLocation W43673037441 @default.
• W4367303744 hasRelatedWork W2025442007 @default.
• W4367303744 hasRelatedWork W2085380381 @default.
• W4367303744 hasRelatedWork W2207954951 @default.
• W4367303744 hasRelatedWork W2273190611 @default.
• W4367303744 hasRelatedWork W2329152519 @default.
• W4367303744 hasRelatedWork W2394841973 @default.
• W4367303744 hasRelatedWork W2414702536 @default.
• W4367303744 hasRelatedWork W4226441803 @default.
• W4367303744 hasRelatedWork W4312777146 @default.
• W4367303744 hasRelatedWork W3037250214 @default.
• W4367303744 isParatext "false" @default.
• W4367303744 isRetracted "false" @default.
• W4367303744 workType "article" @default.